N/A
Completed N=312
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
Source: ClinicalTrials.gov NCT03089983 ↗Enrolled (actual)
312
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: TB Treatment Completion Rates in Prison — 114; 127 Participants — p=0.08
Summary
The purpose of this study is to conduct empiric studies of tuberculosis (TB) among people in prison with and without a history of opioid dependence. A RCT of latent TB infection prevention strategies among HIV+ and HIV- prisoners with high prevalence of hepatitis C (HCV) using standard 40-week daily isoniazid (40H) vs short-course weekly isoniazid + rifapentine (12HR). Investigators will also use this data, and publicly available data to complete agent-based modeling for comparative and cost-effectiveness of various TB screening and treatment strategies among prisoners.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY TB Treatment Completion Rates in Prison |
114; 127 | 0.08 |
| SECONDARY TB Treatment Adherence |
9; 117 | — |
| SECONDARY Discontinuation Due to Experiencing an Adverse Event |
10; 1 | — |
| SECONDARY Acceptability of Starting the Trial |
316 | — |
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria (screening):
- Age ≥ 18 years
- Newly admitted inmate at Kajang Prison
Inclusion Criteria (Trial):
- Age ≥ 18 years HIV-1 seropositivity
- Confirmed LTBI (TST ≥ 5mm if HIV+; TST ≥ 10 mm if HIV-)
- Meets DSM-V criteria for opioid dependence
- >9 months before release (to ensure treatment completion in prison)
- AST/ALT < 3x upper limit normal
Exclusion Criteria
- Unable to provide informed consent
- On a protease inhibitor
- Women who are pregnant or are planning on becoming pregnant
Data sourced from ClinicalTrials.gov (NCT03089983). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.